About Eliquent Japan
Eliquent Japan is a Healthcare company based in Shinjuku (Japan) founded in 2003 by Chris Brunger, and was acquired by Validant in November 2020. Regulatory and consulting services are provided to the biopharma sector. It operates on a Professional Services model. Its chief executive, as recorded, is Naoya Kato. Eliquent Japan offers products and services including PMDA Consultations, Orphan Drug Designation, and NDA Filing. Its focus areas include Biotechnology and Regulatory Consulting. Its legal entity is Eliquent Japan, Inc.
Company details
Eliquent Japan is engaged in offering regulatory consulting services to biotech and pharmaceutical companies aiming to enter the Japanese market. Support is provided through PMDA consultations, orphan drug designations, and NDA filings. Expertise in Japanese regulations and bilingual communication is utilized to ensure seamless development and approval processes. Services cover early-stage evaluations, approval applications, and post-marketing lifecycle management, addressing the unique needs of clients in the biotechnology and pharmaceutical sectors.
- Headquarters Shinjuku, Japan
- Founders Chris Brunger
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website idec-inc.com
- Social LinkedIn
- Acquired by Validant (Nov 2020)
- Legal Name Eliquent Japan, Inc.
Products & Services of Eliquent Japan
Eliquent Japan offers a comprehensive portfolio of products and services, including PMDA Consultations, Orphan Drug Designation, and NDA Filing.
Communication strategies with PMDA are developed and supported.
Support for orphan drug designation strategies is provided.
Comprehensive support for Japan NDA filing is offered.
Investors in Eliquent Japan
Eliquent Japan has secured backing from 1 investor. Prominent investors backing the company include Validant.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Regulatory, compliance, and quality consulting for GxP lifecycles is provided. | 2005 | validant.com | San Francisco, United States |
Investor details for Eliquent Japan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eliquent Japan
5 people are tracked at Eliquent Japan (5 in leadership).
| Name | Role | Group |
|---|---|---|
Chris Brunger | Founder | Leadership |
Naoya Kato | CEO | Leadership |
Mikio Ishizawa | Director Of Marketing And Business Development | Leadership |
Masayoshi Takezawa | Deputy Director Of Business Development | Leadership |
Takao Yamazaki | Director Clinical Pharmacology And Translational Science | Leadership |
Complete people profiles for Eliquent Japan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Eliquent Japan
2 dated milestones of Eliquent Japan across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Eliquent Japan is founded.
- Exit Acquired by Validant.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Eliquent Japan
Eliquent Japan was founded in 2003.
Eliquent Japan is headquartered in Shinjuku, Japan. It is registered at Shinjuku, Tokyo, Japan.
Naoya Kato is the CEO of Eliquent Japan, as recorded in our data.
Eliquent Japan is engaged in offering regulatory consulting services to biotech and pharmaceutical companies aiming to enter the Japanese market. Support is provided through PMDA consultations, orphan drug designations, and NDA filings. Expertise in Japanese regulations and bilingual communication is utilized to ensure seamless development and approval processes. Services cover early-stage evaluations, approval applications, and post-marketing lifecycle management, addressing the unique needs of clients in the biotechnology and pharmaceutical sectors.
Eliquent Japan offers PMDA Consultations, Orphan Drug Designation, and NDA Filing.
Eliquent Japan has 1 investor. Key investors include Validant.
Eliquent Japan operates through Eliquent Japan, Inc..
Yes. Eliquent Japan was acquired by Validant in November 2020.